Nanjing Vazyme Biotech Co Ltd (688105) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has a cash flow conversion efficiency ratio of 0.020x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥75.30 Million ≈ $11.02 Million USD) by net assets (CN¥3.84 Billion ≈ $562.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688105 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Nanjing Vazyme Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nanjing Vazyme Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Imperial Metals Corporation
TO:III
|
0.066x |
|
Giant Manufacturing Co Ltd
TW:9921
|
0.111x |
|
Lotte Tour Dev
KO:032350
|
-0.024x |
|
Colorlight Cloud Tech Ltd. A
SHE:301391
|
N/A |
|
KSB SE & Co. KGaA
XETRA:KSB
|
0.109x |
|
Hangzhou Sunrise Technology Co Ltd
SHE:300360
|
0.057x |
|
Central Pacific Financial Corp
NYSE:CPF
|
0.038x |
|
Tianjin Benefo Tejing Electric Co Ltd
SHG:600468
|
0.001x |
Annual Cash Flow Conversion Efficiency for Nanjing Vazyme Biotech Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Nanjing Vazyme Biotech Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.79 Billion ≈ $554.78 Million |
CN¥233.16 Million ≈ $34.12 Million |
0.061x | +2605.02% |
| 2024-12-31 | CN¥3.94 Billion ≈ $577.07 Million |
CN¥-9.68 Million ≈ $-1.42 Million |
-0.002x | -104.99% |
| 2023-12-31 | CN¥4.03 Billion ≈ $589.61 Million |
CN¥198.40 Million ≈ $29.03 Million |
0.049x | -69.11% |
| 2022-12-31 | CN¥4.61 Billion ≈ $674.90 Million |
CN¥735.17 Million ≈ $107.58 Million |
0.159x | +6.66% |
| 2021-12-31 | CN¥4.13 Billion ≈ $603.95 Million |
CN¥616.80 Million ≈ $90.26 Million |
0.149x | -75.22% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.97 Million |
CN¥803.55 Million ≈ $117.59 Million |
0.603x | +693.51% |
| 2019-12-31 | CN¥200.02 Million ≈ $29.27 Million |
CN¥15.20 Million ≈ $2.22 Million |
0.076x | +415.63% |
| 2018-12-31 | CN¥166.08 Million ≈ $24.30 Million |
CN¥-4.00 Million ≈ $-585.21K |
-0.024x | +5.92% |
| 2017-12-31 | CN¥150.82 Million ≈ $22.07 Million |
CN¥-3.86 Million ≈ $-564.87K |
-0.026x | -- |
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more